Somatic Mutations in Stem and Progenitor Cells in AML
| Registry | NCT01251159 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 30 (Actual) |
| Sponsor | ECOG-ACRIN Cancer Research Group (Network); collaborators: National Cancer Institute (NCI) |
| Conditions | Leukemia |
| Interventions | mutation analysis, polymerase chain reaction, immunologic technique, laboratory biomarker analysis (Genetic, other) |
| Dates | start 2009-05-15, primary completion 2009-06-15, completion 2009-06-15, first posted 2010-12-01, last updated 2017-05-17 |
Related Papers Related Patents Related Grants Related Experts
All trials for Leukemia All trials of mutation analysis All trials of polymerase chain reaction
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is studying bone marrow samples from patients with acute myeloid leukemia.
OBJECTIVES:
* To rigorously examine fractionated hematopoietic stem and progenitor cells from patients with acute myeloid leukemia (AML).
* To define somatic mutations occurring in de novo AML, including the FLT3-ITD, CEBPA, NPM1, TET2, ASXL1, IDH1, and IDH2 mutations.
* To examine what cellular compartments (LT-HSC, ST-HSC, CMP, GMP, and MEP) contain the selected mutations and in what order those mutations occur.
OUTLINE: Archived bone marrow specimens are analyzed for sequencing and detection of mutations by Sanger-based resequencing of PCR amplicons. Results are then compared with the results of age-matched healthy controls.
Sex: All, ages: 16 Years to 60 Years
DISEASE CHARACTERISTICS:
* Diagnosis of acute myeloid leukemia
* Bone marrow samples must meet 1 of the following criteria:
* Normal karyotype from patients enrolled on ECOG-1900 archived at the ECOG Leukemia Tissue Bank
* Live, sortable mononuclear cells prepared at the time of initial diagnosis (slow-frozen in media with 10% DMSO OR fresh cells shipped immediately
* Age-matched healthy control samples from commercial providers
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified